GeoVax Plans 500-Patient Phase 3 for Mpox Vaccine, Data Mid-2027
GOVX is trading near its 52-week low of $0.34 (3.0% above the low) on light trading volume (0.3× avg).
Summary
GeoVax is moving its GEO-MVA mpox/smallpox vaccine directly into a 500-participant pivotal Phase 3 immunobridging study, expected to start in Q4 2026 with results in mid-2027. The company is leveraging an EMA pathway to skip Phase 1/2, accelerating time-to-data. This follows the August 6 news that manufacturing and preclinical milestones were completed, and comes as the CDC reports likely sustained Clade Ib mpox transmission in the U.S. The trial design compares GEO-MVA against the licensed MVA-BN vaccine, setting a clear efficacy bar. With cash only funding operations into September 2026 and a Nasdaq delisting appeal hearing on October 13, the Phase 3 start is a critical near-term catalyst for the stock.
At the time of this announcement, GOVX was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.34 to $16.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.